Barbara Nicke

Nuvisan (Germany) — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index2.6kcitations46works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hippo pathway signaling and YAP/TAZ(10), Cancer-related Molecular Pathways(4), RNA Interference and Gene Delivery(4), Melanoma and MAPK Pathways(4), Retinoids in leukemia and cellular processes(4)

Publications46 total

419 (PB407): Identification and target deconvolution of novel small molecule inhibitors of oncogenic YAP1/TAZ activity
European Journal of Cancer·2024
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling
Cell chemical biology·2024· 9 cited
Abstract 4584: Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I and Rho-GTPase signaling
Cancer Research·2024
Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses
Clinical and Experimental Medicine·2023· 40 citedOpen Access
Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I / Rho-GTPase signaling
2023Open Access
Abstract 6089: Identification of novel YAP/TAZ pathway regulators in the triple-negative breast cancer cell line MDA-MB231 using single-cell CRISPR screening
Cancer Research·2023
JUMP Cell Painting dataset: morphological impact of 136,000 chemical and genetic perturbations
2023· 94 citedOpen Access
Novel YAP1/TAZ Pathway Inhibitors Identified Through Phenotypic Screening with Potent Anti-Tumor Activity via Blockade of GGTase-I / Rho-GTPase Signaling
SSRN Electronic Journal·2023Open Access
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
Nature Cancer·2022· 208 citedOpen Access
Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A
Journal of Medicinal Chemistry·2021· 19 citedOpen Access
MYCN mediates cysteine addiction and sensitizes to ferroptosis
2021· 2 citedOpen Access
Abstract 1722: Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1
Cancer Research·2021· 1 cited
Abstract A29: Genome-wide CRISPR/Cas9 screens for the identification of novel YAP1/TAZ modulators
Molecular Cancer Research·2020
Abstract 3055: Genome-wide CRISPR/Cas9 screen for the identification of novel YAP1/TAZ modulators
Cancer Research·2019
Abstract 3055: Genome-wide CRISPR/Cas9 screen for the identification of novel YAP1/TAZ modulators
Experimental and Molecular Therapeutics·2019
Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2-<i>d</i>]pyrimidine Based <i>in Vitro</i> Probe <b>BAY-885</b> for the Kinase ERK5
Journal of Medicinal Chemistry·2018· 41 citedOpen Access
Crystal structure of Compound 1 with ERK5
2018
Abstract 4973: MYCN mediates cysteine addiction and sensitizes to ferroptosis in cancer cells
Cancer Research·2018
PDE5 inhibition eliminates cancer stem cells via induction of PKA signaling
Cell Death and Disease·2018· 34 citedOpen Access
RNAi as a tool for target discovery in early pharmaceutical research.
PubMed·2016· 4 cited
page 1 of 3Next →

Frequent Co-authors

Julian Downward(14), Ralf Lesche(12), Charles Swanton(11), Stefan Prechtl(8), Martin Lange(8), Julia Kuehnlenz(8), Atanas Kamburov(8), Carlo Stresemann(7), Dominik Mumberg(7), Lisette Potze(7), Craig D. Logsdon(6), Knut Eis(6), Jan Naujoks(6), Alvin Lee(5), Philip East(5), Zoltán Szállási(5), Katrin Nowak‐Reppel(5), Anna Montebaur(5), Patrick Steigemann(5), Philip Lienau(5)